Ortin Global Limited has clarified to the National Stock Exchange of India Limited that the requirement for reporting segment details is not applicable to the company. The firm stated it operates in only one segment, Drugs and Medicines. This disclosure was made in response to an exchange query regarding the financial results for the quarter and year ended March 31, 2026.

The National Stock Exchange of India Limited had sought clarification on June 27, 2026, specifically regarding the absence of segment details in the filing. In its reply dated July 9, 2026, the company explained that since it does not have multiple reportable business segments, the specific disclosure requirement does not apply to its financial reporting structure.

The communication was signed by S. Murali Krishna Murthy, Managing Director of Ortin Global Limited. The company confirmed that its entire operations fall under the Drugs and Medicines category, thereby exempting it from the detailed segment reporting standards applicable to multi-business entities.

Ortin Global Limited disclosed that its promoters and Persons Acting in Concert (PAC) collectively held 1,00,300 equity shares as of March 31, 2026. The company confirmed that no encumbrance was created on these shares, directly or indirectly, during the financial year ended March 31, 2026, except for those already reported to the stock exchanges.

The disclosure was submitted to BSE Limited and the National Stock Exchange of India Limited in compliance with Regulation 31(4) & (5) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing was signed by S. Murali Krishna Murthy on behalf of the promoters.

Shareholding Details

The table below outlines the shareholding status of the promoters and PAC as of the specified date:

Ortin Global Limited, formerly known as Ortin Laboratories Limited, has a BSE scrip code of 539287. The company’s Audit Committee was also marked as a recipient of the disclosure.